Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.

about

Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.

Item

http://www.wikidata.org/entity/Q38611064

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Tumor necrosis factor-α (TNFα) ...... evidence and place in therapy.

@en

type

Item

label

Tumor necrosis factor-α (TNFα) ...... evidence and place in therapy.

@en

prefLabel

Tumor necrosis factor-α (TNFα) ...... evidence and place in therapy.

@en

P1476

Tumor necrosis factor-α (TNFα) ...... evidence and place in therapy

@en

P2093

Valeria Rios Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

Six months open label trial of leflunomide in active ankylosing spondylitis

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

P304

197-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X17706454

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Denis Poddubnyy

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28835779

http://www.w3.org/2001/XMLSchema#string

P932

5557185

http://www.w3.org/2001/XMLSchema#string